Latest Innovation News

ECS Botanics reports a striking 339% quarter-on-quarter growth in its B2C sales, offsetting a slight dip in total revenue as it pivots to a hybrid B2B and B2C business model. The company’s record harvest and new product launches position it for a promising turnaround.

Kingfisher Mining has confirmed two new rare earth element lodes and reported exceptional copper assays, bolstering its position in the Gascoyne region amid ongoing strategic diversification.

Aurora Labs has secured significant contracts in the Defence sector, advancing its micro gas turbine technology and expanding production capabilities following a successful capital raise.

Butn Limited has posted record quarterly revenue and platform originations for Q2 FY25, alongside sustained positive operating cash flow, signaling robust growth and strategic expansion into crypto-backed lending.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

Telix Pharmaceuticals has finalized its acquisition of RLS (USA) Inc., significantly expanding its radiopharmaceutical footprint across the United States with a network of over 30 radiopharmacies.

Kincora Copper Limited has unveiled an updated investor presentation outlining its aggressive push towards Tier-1 copper-gold discoveries, backed by over $60 million in partner funding and ramped-up drilling programs across New South Wales and Mongolia.

Complii FinTech Solutions Ltd reports a robust Q2 FY25 with a $3.048 million cash balance, a net operational cash inflow, and a 12.9% year-on-year increase in Annual Recurring Revenue, driven by strategic divestment and focused growth initiatives.

Veris Limited has reported a remarkable 212% increase in profit before tax for H1 FY25, driven by a strategic pivot towards higher-margin projects and successful restructuring efforts. Despite a slight revenue dip, the company’s strong order book and cash position signal robust growth potential.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.

Swift Networks reports steady cash flow and contract wins in mining and aged care, while unveiling a new feature to capitalize on upcoming aged care legislation.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.